Seminars in Hematology
Volume 44 , Pages S35-S45 , October 2007

Thrombopoietin Mimetic Agents in the Management of Immune Thrombocytopenic Purpura

  • Adrian Newland

      Affiliations

    • Corresponding Author InformationAddress correspondence to Adrian Newland, BA, MB, BCh, MA, FRCP (UK), FRCPath, Pathology and Pharmacy Building, 80, Newark St, The Royal London Hospital, London E1 2 ES, UK.

References 

  1. Odell TT, McDonald T, Detwiler TC. Stimulation of platelet production by serum of platelet-depleted rats. Proc Soc Exp Biol Med. 1961;108:428–431
  2. Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77:1117–1124
  3. Kuter DJ, Begley CG. Recombinant human thrombopoietin: Basic biology and evaluation of clinical studies. Blood. 2002;100:3457–3469
  4. Li Z, Nardi MA, Karpatkin S. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. Blood. 2005;106:572–576
  5. Vadhan-Raj S, Cohen V, Bueso-Ramos C. Thrombopoietic growth factors and cytokines. Curr Hematol Rep. 2005;4:137–144
  6. Kaushansky K. Thrombopoietin. N Engl J Med. 1998;339:746–754
  7. Wolber EM, Jelkmann W. Thrombopoietin: The novel hepatic hormone. News Physiol Sci. 2002;17:6–10
  8. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol. 2000;14(suppl D):60D–66D
  9. Feese MD, Tamada T, Kato Y, Maeda Y, Hirose M, Matsukura Y, et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci U S A. 2004;101:1816–1821
  10. Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109:4607–4616
  11. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994;91:11104–11108
  12. Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999;94:3694–3701
  13. Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, et al. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant. 2000;26:141–145
  14. Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2000;6:25–34
  15. Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000;95:2530–2535
  16. Somlo G, Sniecinski I, ter Veer A, Longmate J, Knutson G, Vuk-Pavlovic S, et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood. 1999;93:2798–2806
  17. Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89:3118–3128
  18. Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Hussein S, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet. 1996;348:1279–1281
  19. Basser RL, Underhill C, Davis I, Green MD, Cebon J, Zalcberg J, et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol. 2000;18:2852–2861
  20. Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997;336:404–409
  21. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelka AP, Freedman RS, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132:364–368
  22. Komatsu N, Okamoto T, Yoshida T. Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (plt) in patients with aplastic anemia (AA) nad myelodysplastic syndrome (MDS). Blood. 2000;96:296a;(abstr)
  23. Harker LA, Carter RA, Marzec UM. Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy. Blood. 1998;92(suppl 1):707a;(abstr)
  24. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood. 2002;100:728–730
  25. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science. 1997;276:1696–1699
  26. de Serres M, Ellis B, Dillberger JE, Rudolph SK, Hutchins JT, Boytos CM, et al. Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: Evaluation of the potential for thrombopoietin neutralizing antibody production in man. Stem Cells. 1999;17:203–209
  27. Frederickson S, Renshaw MW, Lin B, Smith LM, Calveley P, Springhorn JP, et al. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. Proc Natl Acad Sci U S A. 2006;103:14307–14312
  28. Cerneus D, Brown K, Harris R, End D, Molloy C, Yurkow E, et al. Stimulation of platelet production in healthy volunteers by a novel pegylated peptide-based thrombopoietin (TPO) receptor agonist. ASH Annual Meeting Abstracts. 2005;106:1249
  29. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76:628–638
  30. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672–1681
  31. Newland A, Caulier MT, Kappers-Klunne M, Schipperus MR, Lefrere F, Zwaginga JJ, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol. 2006;135:547–553
  32. Bussel JB, Kuter DJ, George JN, Aledort LM, Lichtin AE, Lyons RM, et al. Long-term dosing of AMG 531 is effective and well tolerated in thrombocytopenic patients with immune thrombocytopenic purpura. ASH Annual Meeting Abstracts. 2005;106:220
  33. Kuter D, Bussel J, George J, Aledort L, Lichtin A, Lyons R, et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update. ASH Annual Meeting Abstracts. 2006;108:476
  34. Kantarjian HM, Giles FJ, Fenaux P, Becker PS, Boruchov AM, Bowen DT, et al. Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with myelodysplastic syndrome (MDS): Preliminary results of a phase 1/2 study. J Clin Oncol. 2007;25:7032;(abstr)
  35. Duffy KJ, Darcy MG, Delorme E, Dillon SB, Eppley DF, Erickson-Miller C, et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem. 2001;44:3730–3745
  36. Duffy KJ, Price AT, Delorme E, Dillon SB, Duquenne C, Erickson-Miller C, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics. J Med Chem. 2002;45:3576–3578
  37. Duffy KJ, Shaw AN, Delorme E, Dillon SB, Erickson-Miller C, Giampa L, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules (1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics). J Med Chem. 2002;45:3573–3575
  38. Luengo JI, Duffy KJ, Shaw AN, Delorme E, Wiggall KJ, Giampa L, et al. Discovery of SB-497115, a small-molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia. ASH Annual Meeting Abstracts. 2004;104:2910;(abstr)
  39. USP Dictionary of USAN and International Drug Names. 2005 USP Dictionary (suppl 5)
  40. Erickson-Miller C, Delorme E, Giampa L, Hopson C, Valoret E, Tian S-S, et al. Biological activity and selectivity for tpo receptor of the orally bioavailable, small molecule Tpo receptor agonist, SB-497115. ASH Annual Meeting Abstracts. 2004;104:2912;(abstr)
  41. Erickson-Miller CL, DeLorme E, Tian SS, Hopson CB, Stark K, Giampa L, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005;33:85–93
  42. Erhardt J, Erickson-Miller CL, Tapley P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. ASH Annual Meeting Abstracts. 2004;104:3888;(abstr)
  43. Erickson-Miller CL, Delorme E, Iskander M, Giampa L, Hopson CB, Luengo J, et al. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist. ASH Annual Meeting Abstracts. 2004;104:2909;(abstr)
  44. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109:4739–4741
  45. Bussel JB, Cheng G, Saleh M, Kovaleva L, Stone N, Mayer B, et al. Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): A randomized, double-blind, placebo-controlled trial of eltrombopag, an oral platelet growth factor. ASH Annual Meeting Abstracts. 2006;108:475;(abstr)
  46. Bussel JB, Provan A, Shamsi T, Cheng G, Kovaleva L, Stone N, et al: Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: A phase III study. 12th Congress of the European Hematology Association, Vienna, Austria, June 7–10, 2007 (abstr 0390)
  47. McHutchison JG, Afdhal N, Shiffman ML, Gordon S, Mills P, Sigal S, et al: Efficacy and safety of eltrombopag, an oral platelet growth factor, in subjects with HCV associated thrombocytopenia: Preliminary results from a phase II multicenter, randomised, placebo controlled, double-blind, dose-ranging study. Proceeding of the Annual Meeting of the American Association for the Study of Liver Diseases 2006 (abstr LB3)
  48. Suzuki K-i, Abe M, Fukushima-Shintani M, Sugasawa K, Hirayama F, Kawasaki T, et al. YM477, a novel orally-active thrombopoietin receptor agonist. ASH Annual Meeting Abstracts. 2005;106:2298;(abstr)
  49. Desjardins RE, Tempel DL, Lucek R, Kuter DJ. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. ASH Annual Meeting Abstracts. 2006;108:477;(abstr)
  50. Orita T, Tsunoda H, Yabuta N, Nakano K, Yoshino T, Hirata Y, et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood. 2005;105:562–566
  51. Kai M, Motoki K, Yoshida H, Tsuruhata K, Endo C, Muto M, et al. Domain subclass conversion improved activity of anti-Mpl agonist antibodies in the form of whole IgG. ASH Annual Meeting Abstracts. 2006;108:1134;(abstr)
  52. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241–3248
  53. Yanagida M, Ide Y, Imai A, Toriyama M, Aoki T, Harada K, et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol. 1997;99:739–745
  54. Ulich TR, del Castillo J, Senaldi G, Kinstler O, Yin S, Kaufman S, et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood. 1996;87:5006–5015
  55. Villeval JL, Cohen-Solal K, Tulliez M, Giraudier S, Guichard J, Burstein SA, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997;90:4369–4383
  56. Yan XQ, Lacey D, Fletcher F, Hartley C, McElroy P, Sun Y, et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood. 1995;86:4025–4033
  57. Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol. 2002;117:844–850
  58. Harker LA. Platelets in thrombotic disorders: Quantitative and qualitative platelet disorders predisposing to arterial thrombosis. Semin Hematol. 1998;35:241–252
  59. Harker LA, Hunt P, Marzec UM, Kelly AB, Tomer A, Hanson SR, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood. 1996;87:1833–1844

 STATEMENT OF CONFLICT OF INTEREST: Dr Newland has received grant/research support from Gilead and Amgen, and has received honoraria from Gilead and Amgen; he will discuss the unlabeled/unapproved use of rituximab, eltrombobag, and AMG 531 for idiopathic thrombocytopenic purpura.

PII: S0037-1963(07)00162-X

doi: 10.1053/j.seminhematol.2007.11.005

Seminars in Hematology
Volume 44 , Pages S35-S45 , October 2007

Article Tools

* Image Usage & Resolution